The $200m corporate venturing unit of Baxter International, Baxter Ventures, leads a $38m B round into Naurex, a US-based drug developer which has received technologies from Northwestern University.
Baxter Ventures, established by the drug company Baxter International, has led a $38m Series B round into Naurex, a clinical-stage drug company developing treatments in psychiatry and neurology that utilises treatments developed at Northwestern University. Naurex’s treatments are developed from the work of Joseph R. Moskal and his colleagues at the Falk Center for Molecular Therapeutics…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
